Background-Lp(a) lipoprotein has structural homology with plasminogen and has been shown to inhibit plasminogen activation in vitro. Objective-To determine whether the serum concentration of Lp(a) lipoprotein present when streptokinase was given in acute myocardial infarction influenced the outcome as judged by electrocardiographic methods. Patients and design-Serum Lp(a) lipoprotein concentration was measured in 135 consecutive patients admitted with a diagnosis of acute myocardial infarction who received streptokinase treatment. Recovery from myocardial injury was assessed by the reduction in the sum of ST segment elevation measured from the J point (SiJ) in the electrocardiogram immediately before streptokinase was given compared with that three hours later. Results-The serum Lp(a) lipoprotein concentrations were measured within 12 hours of the onset of symptoms of myocardial infarction and were higher than in healthy reference populations. Recovery from myocardial infarction could be assessed from the STJ in 116 patients (86% of the series). Those in whom it could not had bundle branch block, left ventricular hypertrophy, did not survive three hours, or had started intravenous nitrate treatment or some other clinical procedure before or at the time the second electrocardiogram was to be recorded. Patients with reductions in STJ after streptokinase that were > 4 mm (the median decrease) had mean (range) serum Lp(a) lipoprotein concentrations of 410 (0.8-220) mg/dl and those with a smaller reduction in STJ had concentrations of 29-1 (1-7-151) mgldl. The difference was not statistically significant.
Objective-To determine whether the serum concentration of Lp(a) lipoprotein present when streptokinase was given in acute myocardial infarction influenced the outcome as judged by electrocardiographic methods. Patients and design-Serum Lp(a) lipoprotein concentration was measured in 135 consecutive patients admitted with a diagnosis of acute myocardial infarction who received streptokinase treatment. Recovery from myocardial injury was assessed by the reduction in the sum of ST segment elevation measured from the J point (SiJ) in the electrocardiogram immediately before streptokinase was given compared with that three hours later. Results-The serum Lp(a) lipoprotein concentrations were measured within 12 hours of the onset of symptoms of myocardial infarction and were higher than in healthy reference populations. Recovery from myocardial infarction could be assessed from the STJ in 116 patients (86% of the series). Those in whom it could not had bundle branch block, left ventricular hypertrophy, did not survive three hours, or had started intravenous nitrate treatment or some other clinical procedure before or at the time the second electrocardiogram was to be recorded. Patients with reductions in STJ after streptokinase that were > 4 mm (the median decrease) had mean (range) serum Lp(a) lipoprotein concentrations of 410 (0.8-220) mg/dl and those with a smaller reduction in STJ had concentrations of 29-1 (1-7-151) mgldl. The difference was not statistically significant.
Conclusion-In this study Lp(a) lipoprotein concentration did not significantly influence the outcome of thrombolytic treatment with streptokinase. (Br HeartrJ 1994; 71:316-321) Thrombolysis is well established in the treatment of myocardial infarction1-3 and has been shown to increase patency of the infarct related coronary artery,4 reduce the size of the myocardial infarct,5 preserve left ventricular dimensions and function,67 and reduce both early and late mortality.89
The Lp(a) lipoprotein is widely held to be an important risk factor in coronary heart disease. High serum Lp(a) lipoprotein concentrations are associated with an increased prevalence of angina pectoris, myocardial infarction, and coronary artery disease assessed angiographically.1S-2 The Lp(a) lipoprotein has close structural homology with plasminogen13 and can impede fibrinolysis at the surface of cultured human endothelial cells.14 Enormous doses of thrombolytic agent are used in the treatment of myocardial infarction, however, which might be predicted from in vitro studies, to overwhelm any competition by Lp(a) lipoprotein."5 None the less in vivo similar kinetic considerations may not apply locally at a thrombosis in a coronary artery and the possibility remains that Lp(a) lipoprotein might impede plasminogen activation or compete with plasminogen and plasmin treatment impeding breakdown of the fibrin clot.
We therefore investigated the influence of the prevailing serum concentration of Lp(a) lipoprotein on the clinical outcome of acute myocardial infarction treated with streptokinase.
Patients and methods

PATIENTS
Approval for this study was obtained from the Clinical Ethics Committee of our hospital, and all patients participating gave their informed consent. All patients admitted to the coronary care unit with a diagnosis of acute myocardial infarction were treated with streptokinase unless there were specific contraindications-namely, more than 12 hours since the onset of continuous chest pain; confirmed peptic ulcer within the previous six months; current infusion were also measured. The decline in the sum of ST elevation in the electrocardiogram has previously been shown to correlate well with recovery from myocardial injury and reperfusion of the infarct-related artery. '7-19 Of the 135 patients studied 116 had electrocardiograms that could be analysed. Six could not because of left or right bundle branch block or left ventricular hypertrophy, four could not because the patients died before the second electrocardiogram, and nine were excluded because intravenous nitrate infusion had been given to the patients in the interval between the first and second electrocardiogram or the second electrocardiogram could not be recorded at three hours because the patient's condition demanded some other more urgent clinical procedure at the time.
Electrocardiograms were performed daily during the 48 hour or longer stay on the coronary care unit and again before discharge from hospital, and the clinical progress of the patient was monitored by one of us. The electrocardiogram recorded before discharge from hospital was used to calculate a Selvester score, which correlates well with the size of the myocardial infarction.202' Sixty five of the patients had coronary angiography at a median of six days after thrombolysis, and these films were used to check for patency of the infarct related artery with a protocol from the Thrombolysis in Myocardial Infarction Study.4 Coronary angiography was performed in all patients under the age of 50 for men and 65 for women (n = 24) and in patients with recurrent chest pain after myocardial infarction (n = 39), or for other clinical indications (n = 2), unless there were contraindications such as massive myocardial infarction with poor ensuing left ventricular function.
The films were independently scrutinised by two experienced angiographers on different occasions to assess the patency of the infarct related artery. <1-5mm Table 1 shows the clinical characteristics of the patients. The patients tended to have high cholesterol and triglycerides and low high density lipoprotein cholesterol compared with typical values for a healthy British population. The serum Lp(a) lipoprotein values were high, the median value in healthy local people being 10 mg/dl." The site of the myocardial infarction on electrocardiographic criteria was inferior in 48%, anterior in 45%, posterior in 4%, and lateral in 3%. The median (range) time between the onset of chest pain and the start of the intravenous infusion of streptokinase was three (0-5-14) hours.
MORTALITY
Seventeen (12-6%) of the 135 patients investigated died during the next three months. The median (range) serum Lp(a) lipoprotein concentration immediately before streptokinase in those who died was 28-8 (1-7-85-0) mg/dl, which was not significantly different from those who survived (34 0 (0 8-220-0) mg/dl). There was no significant relation between serum Lp(a) lipoprotein concentrations and mortality within the first three months or heart failure treated within the first three days.
ELECTROCARDIOGRAPHIC INDICES OF OUTCOME OF THROMBOLYTIC TREATMENT
When patients whose ST segment recovery exceeded the median rate were, compared with those with rates below this value (table 2) there was a tendency for serum Lp(a) lipoprotein concentrations to be higher in patients whose ST segments returned rapidly towards the isoelectric line than in those in whom it was slower to return. This was so regardless of the measure of ST segment elevation used.
The difference was not significant by two tailed tests, which we considered should be used because our original hypothesis was that high circulating Lp(a) lipoprotein at the time of streptokinase infusion might unfavourably affect its outcome. There was no significant correlation between the serum Lp(a) lipoprotein concentration and size of the myocardial infarction assessed by electrocardiography.
CORONARY ANGIOGRAPHIC OUTCOME OF THROMBOLYTIC TREATMENT The 62 patients selected to have coronary angiography were younger than the rest. They were also minimally more obese (p < 0 05) but in most other respects their clinical characteristics were similar to the others. There were also no significant differences in serum Lp(a) lipoprotein concentrations or in other lipid or lipoprotein variables between patients with occluded and patent infarct related coronary arteries (table 3) . There was a trend for higher coronary artery disease scores and a tendency for previous myocardial infarction in patients with occluded infarct related coronary arteries.
HAEMATOLOGICAL RESPONSE TO THROMBOLYTIC TREATMENT
Before the streptokinase infusion the mean (SD) plasma fibrinogen was 3-26(1l11) g/l (n = 71) and three hours afterwards it was 0 67(0 45) g/l (n = 77). The pretreatment plasma fibrinogen in patients with occluded infarct related coronary arteries (3-53(1 15) g/l; n = 9) and the fibrinogen response to streptokinase (079(077) gil; n = 10) were not significantly different from those with patent arteries (3-19(084) gil; n = 21 and 0 74(0 56) g/l; n = 25). Furthermore plasma fibrinogen concentration did not differ between patients with a > 4 mm fall in ST segment elevation and those in whom it was < 4 mm. There was no significant correlation between the change in plasma fibrinogen from zero to three hours after the start of streptokinase treatment and the serum Lp(a) lipoprotein concentration before streptokinase infusion (Kendall's tau = 0-106, NS). The Lp(a) lipoprotein is distinguished from other lipoproteins by possessing an apolipoprotein, apolipoprotein(a), which is a mutation of plasminogen. It has a protease domain structurally similar to that of plasminogen, but is not activated to lyse fibrin by plasminogen activators. Furthermore in place of the short series of five kringles present in plasminogen, Lp(a) lipoprotein has a long series of kringles due to repetition of kringles homologous to the fourth kringle of plasminogen. The number of these repeats is determined by a single genetic locus and is responsible both for the genetic variation in the molecular mass of apolipoprotein(a) and largely for its circulating concentration.0
Because of its resemblance to plasminogen and its lack of activation by known plasminogen activating factors, Lp(a) lipoprotein seems an obvious candidate to inhibit fibrinolysis competitively. There are in vitro studies that show that it will bind to plasminogen receptors3" and to fibrin32 and that it will inhibit plasminogen activation.'4 One attempt to show that Lp(a) lipoprotein does bind to plasminogen receptors in vivo, however, proved negative." There have been three previous studies in which in vivo evidence of an effect of Lp(a) lipoprotein on thrombolysis has been sought with the clinical outcome of patients undergoing thrombolytic treatment for acute myocardial infarction as the model.'4'6 In none of these reports was streptokinase used. Nor was the electrocardiographic response investigated. These studies were small, involving only 20-50 patients, and because coronary angiography could not be undertaken without a clinical indication (as in our present study) they may have been confounded by selection bias. The results of these studies, like ours, showed no effect of Lp(a) lipoprotein on the patency of infarct-related coronary arteries.
We considered that the electrocardiographic response to thrombolytic treatment might provide an insight into the in vivo effect of Lp(a) lipoprotein in a larger, less biased series of patients than was possible with coronary angiography. This proved to be the case because it was possible to assess the rate of recovery of the ST segment elevation in 86% of a series of 135 patients. (The remainder could not be assessed as their electrocardiograms were unsuitable and showed abnormalities such as left bundle branch block and left ventricular hypertrophy). One factor limiting the return of the ST segment to the isoelectric line when thrombolytic treatment has been given is whether the ischaemic myocardium is successfully reperfused.'9 We therefore reasoned that were Lp(a) lipoprotein to interfere with thrombolysis a greater proportion of patients with high concentrations of serum Lp(a) lipoprotein at the time they received streptokinase would show a slower recovery in ST segment elevation. We found no evidence for this possibility in our study. Indeed, the patients with the more rapid decline of ST segments had a median concentration of Lp(a) A second hypothesis to explain our electrocardiographic findings might be that they result, not so much from greater reperfusion of the myocardium in the patients with high serum Lp(a) lipoprotein concentrations, but that they represent a greater degree of reperfusion injury in patients with low serum Lp(a) lipoprotein concentrations. If this were the case, its explanation might be that Lp(a) lipoprotein was acting to limit the extent of bleeding into the perinfarction zone after dissolution of the clot. Such bleeding leads to the morbid anatomical appearance of "red infarction"38 and has been implicated as the cause of reperfusion injury (associated with prolonged elevation of ST segments due to persisting "current-of-injury"), slower recovery from myocardial injury, and eventually impaired ventricular remodelling.39 40 Both coronary thrombolysis and red infarction can occur spontaneously during myocardial infarction, although they are more likely to do so if a thrombolytic agent has been given.
Thus although Lp(a) lipoprotein may be related to the risk of developing coronary atheroma, our findings do not exclude a possible beneficial effect during myocardial infarction. This suggests caution in the use of treatments aimed at lowering serum Lp(a) lipoprotein concentrations in patients at risk of coronary heart disease, because there may be advantages as well as disadvantages from a high concentration of circulating Lp(a) lipoprotein. Any in vivo effects it might have on coagulation are difficult to predict from in vitro experiments. We believe that serum Lp(a) lipoprotein concentrations should be correlated with the clinical outcome in larger trials of thrombolytic treatment.
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